- |||||||||| ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal: Undifferentiated Embryonal Sarcoma of the Liver (UESL): A Single-Center Experience and Review of the Literature. (Pubmed Central) - Sep 9, 2017 Patients were treated with multimodal treatment approaches including primary surgical resection, neoadjuvant and/or adjuvant chemotherapy, and liver transplantation resulting in overall survival reported between 20% and 100% with significant improvement over the recent years. We show that complete tumor removal remains the key element of treatment and our single-institutional experience and data in the published literature suggest that combination chemotherapy with ifosfamide and doxorubicin to facilitate complete surgical resection is an effective approach to cure children with UESL.
- |||||||||| Journal: Osteosarcoma With Apparent Ewing Sarcoma Gene Rearrangement. (Pubmed Central) - Sep 9, 2017
Hybridization capture-based next-generation DNA sequencing showed evidence of complex genomic rearrangements, absence of known pathogenic Ewing-like chromosome translocations, and deletions RB1, PTCH1, and ATRX, supporting the diagnosis of osteosarcoma. This illustrates the potential of clinical genomic profiling to improve diagnosis and enable specifically targeted therapies for cancers with complex pathologies.
- |||||||||| Journal: Antimicrobial sulfonamides clear latent Kaposi sarcoma herpesvirus infection and impair MDM2-p53 complex formation. (Pubmed Central) - Sep 9, 2017
Here we show that sulfonamide antibiotics are able to suppress the KSHV latent state in permanently infected BC3 lymphoma cells and interfere with the formation of the MDM2-p53 complex that KSHV seemingly needs to support latency and to trigger tumor cell transformation. These findings detected a new molecular target for the activity of sulfonamides and offer a new potential perspective for treating KSHV-induced lymphoproliferative diseases.The Journal of Antibiotics advance online publication, 14 June 2017; doi:10.1038/ja.2017.67.
- |||||||||| Journal: RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma. (Pubmed Central) - Sep 8, 2017
DDX3 inhibition altered the Ewing sarcoma cellular proteome, especially proteins involved in DNA replication, mRNA translation and proteasome function. These data support further investigation of the role of DDX3 in sarcomas, advancement of RK-33 to Ewing sarcoma clinical trials and development of RNA helicase inhibition as a novel anti-neoplastic strategy.Oncogene advance online publication, 14 September 2015; doi:10.1038/onc.2015.336.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, PD(L)-1 Biomarker, IO biomarker: AcS (clinicaltrials.gov) - Sep 8, 2017 P2, N=300, Recruiting, Trial primary completion date: Dec 2016 --> Apr 2019 Not yet recruiting --> Recruiting
- |||||||||| Journal: Rhabdomyosarcoma of the Breast in Adolescent and Young Adult (AYA) Women. (Pubmed Central) - Sep 6, 2017
In total, 4/10 of all AYA females had breast involvement. Routine examination or imaging of the breasts in AYAs with RMS is not currently standard practice at diagnosis or follow-up, but this analysis suggests it should be considered in female AYA patients.
- |||||||||| Avastin (bevacizumab) / Roche
Trial completion: Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients (clinicaltrials.gov) - Sep 5, 2017 P2, N=19, Completed, Routine examination or imaging of the breasts in AYAs with RMS is not currently standard practice at diagnosis or follow-up, but this analysis suggests it should be considered in female AYA patients. Recruiting --> Completed
- |||||||||| Journal: An Update on Tumors of the Lacrimal Gland. (Pubmed Central) - Sep 3, 2017
In contrast, the cornerstone in management of lymphoid lesions is chemotherapy, often including a monoclonal antibody. This article presents an update on the clinical, radiological, histological, and molecular features, along with treatment strategies for tumors of the lacrimal gland.
- |||||||||| Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Metastases: Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy (clinicaltrials.gov) - Sep 1, 2017 P2, N=56, Recruiting, This article presents an update on the clinical, radiological, histological, and molecular features, along with treatment strategies for tumors of the lacrimal gland. Trial primary completion date: Dec 2017 --> Dec 2018
- |||||||||| Journal: Natural killer cell adoptive immunotherapy: Coming of age. (Pubmed Central) - Aug 31, 2017
Among the methods described are the use of bioreactors for scaling up production and expansion of NK cells in the presence of interleukins and feeder cells. We also discuss novel methodologies that optimize the generation of clinical grade NK-cell products for AI.
- |||||||||| Review, Journal: Treatment pathway of bone sarcoma in children, adolescents, and young adults. (Pubmed Central) - Aug 30, 2017
on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
- |||||||||| Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Enrollment change, Combination therapy, Metastases: Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (clinicaltrials.gov) - Aug 29, 2017 P3, N=510, Active, not recruiting, This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. N=3331 --> 510
- |||||||||| imatinib / Generic mfg.
Trial completion, Trial primary completion date, Stroma: Five Year Adjuvant Imatinib Mesylate (Gleevec (clinicaltrials.gov) - Aug 28, 2017 P2, N=91, Completed, Trial primary completion date: Nov 2016 --> Sep 2018 Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Dec 2016
- |||||||||| Fyarro (nanoparticle albumin-bound rapamycin) / Aadi Biosci, Opdivo (nivolumab) / BMS
Enrollment open, PD(L)-1 Biomarker, IO biomarker, Metastases: Nivolumab (Opdivo (clinicaltrials.gov) - Aug 27, 2017 P1b, N=40, Recruiting, Trial primary completion date: Mar 2020 --> Aug 2019 Not yet recruiting --> Recruiting
|